FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2312380467> ?p ?o ?g. }

• W2312380467 abstract "Abstract #2107 Introduction: Trastuzumab was recently approved for adjuvant use in HER2+ breast cancer. Adjuvant treatment should result in a reduction in recurrences, but this has not been estimated from a US population perspective. Methods: We estimated the number of HER2+ breast cancers in the US in 2005 using SEER data. Because HER2 status is not available in SEER, the number of HER2+ patients was estimated using the known relationship between HER2 status and both estrogen receptor (ER) and progesterone receptor (PR) status. Patients with no ER or PR results were assumed to have no HER2 testing. HER2+ proportions for remaining ER+/PR+, ER+/PR-, ER-/PR+ and ER-/PR- patients were estimated from published data and applied to patients diagnosed in the 17 SEER registries. The resulting rates were applied to the 2005 US female population counts. Estimated HER2+ patient counts were stratified by nodal status (+/-), and age (30-50, 50-70, and >70 years). Patients with significant underlying cardiovascular (CV) disease were assumed not to use trastuzumab. Underlying recurrence rates were pooled across studies that compared doxorubicin and cyclophosphamide followed by a taxane (AC-T) versus the same regimen plus 52 weeks of trastuzumab (AC-TH). Rates were stratified by nodal status. The relative risk of recurrence with trastuzumab (0.53) was assumed to be constant across subgroups based on published data, and assumed to persist for 5 years. One study (NSABP B-31) estimated the proportion experiencing a CV event (primarily defined as ejection fraction decline below threshold or dyspnea with normal activity) based on 5-year follow-up. Probabilistic model inputs were used to reflect the likelihood of possible values where possible. The results were run using 5,000 replications and reported as the mean and middle 95% of the distribution using @Risk (Palisade Corp., Ithaca, NY). Results: The model estimated that there are approximately 28,500 (95% interval 26,400 to 31,500) patients who could be diagnosed with HER2+ breast cancer in one year in the US, 6,128 (95% interval 4,292 to 8,600) of whom will have a recurrence within 5 years, and up to 2,619 of whom (95% interval 1,506 to 3,701) who could be prevented from disease recurrence with trastuzumab use. The number of patients who might experience a CV event is approximately 941 (95% interval 510 to 1,395) giving a ratio of 2.7 recurrences prevented for every CV event (95% interval 1.4 to 5.6). Conclusion: Trastuzumab is capable of preventing at least 2,600 recurrences within 5 years after its initial year of use. Its most clinically important side effect, a CV event, is likely to appear once for every 2.7 recurrences that are prevented, although many cases are asymptomatic and reversible. Extrapolated over 20 years, targeting HER2+ tumors in the adjuvant setting could prevent as many as 50,000 HER2+ patients from recurrence with important clinical, humanistic and economic consequences for patients, physicians and payors. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 2107." @default.
• W2312380467 created "2016-06-24" @default.
• W2312380467 creator A5018773741 @default.
• W2312380467 creator A5019132733 @default.
• W2312380467 creator A5024474312 @default.
• W2312380467 creator A5066583016 @default.
• W2312380467 creator A5072015843 @default.
• W2312380467 date "2009-01-15" @default.
• W2312380467 modified "2023-09-27" @default.
• W2312380467 title "Estimating recurrences prevented from using trastuzumab in adjuvant breast cancer in the United States." @default.
• W2312380467 doi "https://doi.org/10.1158/0008-5472.sabcs-2107" @default.
• W2312380467 hasPublicationYear "2009" @default.
• W2312380467 type Work @default.
• W2312380467 sameAs 2312380467 @default.
• W2312380467 citedByCount "0" @default.
• W2312380467 crossrefType "proceedings-article" @default.
• W2312380467 hasAuthorship W2312380467A5018773741 @default.
• W2312380467 hasAuthorship W2312380467A5019132733 @default.
• W2312380467 hasAuthorship W2312380467A5024474312 @default.
• W2312380467 hasAuthorship W2312380467A5066583016 @default.
• W2312380467 hasAuthorship W2312380467A5072015843 @default.
• W2312380467 hasConcept C121608353 @default.
• W2312380467 hasConcept C126322002 @default.
• W2312380467 hasConcept C143998085 @default.
• W2312380467 hasConcept C2777511904 @default.
• W2312380467 hasConcept C2777863537 @default.
• W2312380467 hasConcept C2779786085 @default.
• W2312380467 hasConcept C2781413609 @default.
• W2312380467 hasConcept C2908647359 @default.
• W2312380467 hasConcept C29456083 @default.
• W2312380467 hasConcept C530470458 @default.
• W2312380467 hasConcept C71924100 @default.
• W2312380467 hasConcept C99454951 @default.
• W2312380467 hasConceptScore W2312380467C121608353 @default.
• W2312380467 hasConceptScore W2312380467C126322002 @default.
• W2312380467 hasConceptScore W2312380467C143998085 @default.
• W2312380467 hasConceptScore W2312380467C2777511904 @default.
• W2312380467 hasConceptScore W2312380467C2777863537 @default.
• W2312380467 hasConceptScore W2312380467C2779786085 @default.
• W2312380467 hasConceptScore W2312380467C2781413609 @default.
• W2312380467 hasConceptScore W2312380467C2908647359 @default.
• W2312380467 hasConceptScore W2312380467C29456083 @default.
• W2312380467 hasConceptScore W2312380467C530470458 @default.
• W2312380467 hasConceptScore W2312380467C71924100 @default.
• W2312380467 hasConceptScore W2312380467C99454951 @default.
• W2312380467 hasLocation W23123804671 @default.
• W2312380467 hasOpenAccess W2312380467 @default.
• W2312380467 hasPrimaryLocation W23123804671 @default.
• W2312380467 isParatext "false" @default.
• W2312380467 isRetracted "false" @default.
• W2312380467 magId "2312380467" @default.
• W2312380467 workType "article" @default.